The expression of CD56 antigen is associated with poor prognosis in patients with acute myeloid leukemia
Autor(a) principal: | |
---|---|
Data de Publicação: | 2011 |
Outros Autores: | , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Revista brasileira de hematologia e hemoterapia (Online) |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842011000300012 |
Resumo: | BACKGROUND: The expression of CD56 is considered a bad prognostic factor for overall survival, lower rates or short complete remission and extramedullary invasion but the results are controversial. The importance of validating new prognostic parameters in acute leukemias was the reason to investigate the CD56 expression in blast cells of patients with acute myeloid leukemia. METHODS: A cohort of 48 patients treated at Hospital de Clinicas de Porto Alegre and diagnosed with acute myeloid leukemia as classified by the French-American-British group (FAB) criteria using cell morphology, cytochemistry and flow cytometry were evaluated. RESULTS: Eight cases (16.7%) were CD56 positive without correlation to age or gender. The highest incidence of CD56 positivity was in FAB subtypes M4 and M5. The death rate during induction was not significantly different between patients with and without CD56 expression (62.5% vs. 27.5%; p-value = 0.097). However, patients that expressed CD56 had significantly lower overall survival than those who did not (mean 4.0 months vs. 14.5 months; p-value = 0.03). CONCLUSIONS: The data suggest that expression of CD56 in acute myeloid leukemia may be indicative of poor prognosis because it is associated with a shorter overall survival. The death rate during induction was not significantly different despite an apparent difference in proportions between groups. |
id |
ABHHTC-1_276176a7e1bfff0df1bfaf5073ea0996 |
---|---|
oai_identifier_str |
oai:scielo:S1516-84842011000300012 |
network_acronym_str |
ABHHTC-1 |
network_name_str |
Revista brasileira de hematologia e hemoterapia (Online) |
repository_id_str |
|
spelling |
The expression of CD56 antigen is associated with poor prognosis in patients with acute myeloid leukemiaAntigens, CD56Leukemia, MyeloidPrognosisBACKGROUND: The expression of CD56 is considered a bad prognostic factor for overall survival, lower rates or short complete remission and extramedullary invasion but the results are controversial. The importance of validating new prognostic parameters in acute leukemias was the reason to investigate the CD56 expression in blast cells of patients with acute myeloid leukemia. METHODS: A cohort of 48 patients treated at Hospital de Clinicas de Porto Alegre and diagnosed with acute myeloid leukemia as classified by the French-American-British group (FAB) criteria using cell morphology, cytochemistry and flow cytometry were evaluated. RESULTS: Eight cases (16.7%) were CD56 positive without correlation to age or gender. The highest incidence of CD56 positivity was in FAB subtypes M4 and M5. The death rate during induction was not significantly different between patients with and without CD56 expression (62.5% vs. 27.5%; p-value = 0.097). However, patients that expressed CD56 had significantly lower overall survival than those who did not (mean 4.0 months vs. 14.5 months; p-value = 0.03). CONCLUSIONS: The data suggest that expression of CD56 in acute myeloid leukemia may be indicative of poor prognosis because it is associated with a shorter overall survival. The death rate during induction was not significantly different despite an apparent difference in proportions between groups.Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular2011-06-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842011000300012Revista Brasileira de Hematologia e Hemoterapia v.33 n.3 2011reponame:Revista brasileira de hematologia e hemoterapia (Online)instname:Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)instacron:ABHHTC10.5581/1516-8484.20110054info:eu-repo/semantics/openAccessAlegretti,Ana PaulaBittar,Christina MatzenbacherBittencourt,RosanePiccoli,Amanda KirchnerSchneider,LaianaSilla,Lúcia MarianoBó,Suzane DalXavier,Ricardo Machadoeng2011-07-27T00:00:00Zoai:scielo:S1516-84842011000300012Revistahttp://www.rbhh.org/pt/archivo/https://old.scielo.br/oai/scielo-oai.phpsbhh@terra.com.br||secretaria@rbhh.org1806-08701516-8484opendoar:2011-07-27T00:00Revista brasileira de hematologia e hemoterapia (Online) - Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)false |
dc.title.none.fl_str_mv |
The expression of CD56 antigen is associated with poor prognosis in patients with acute myeloid leukemia |
title |
The expression of CD56 antigen is associated with poor prognosis in patients with acute myeloid leukemia |
spellingShingle |
The expression of CD56 antigen is associated with poor prognosis in patients with acute myeloid leukemia Alegretti,Ana Paula Antigens, CD56 Leukemia, Myeloid Prognosis |
title_short |
The expression of CD56 antigen is associated with poor prognosis in patients with acute myeloid leukemia |
title_full |
The expression of CD56 antigen is associated with poor prognosis in patients with acute myeloid leukemia |
title_fullStr |
The expression of CD56 antigen is associated with poor prognosis in patients with acute myeloid leukemia |
title_full_unstemmed |
The expression of CD56 antigen is associated with poor prognosis in patients with acute myeloid leukemia |
title_sort |
The expression of CD56 antigen is associated with poor prognosis in patients with acute myeloid leukemia |
author |
Alegretti,Ana Paula |
author_facet |
Alegretti,Ana Paula Bittar,Christina Matzenbacher Bittencourt,Rosane Piccoli,Amanda Kirchner Schneider,Laiana Silla,Lúcia Mariano Bó,Suzane Dal Xavier,Ricardo Machado |
author_role |
author |
author2 |
Bittar,Christina Matzenbacher Bittencourt,Rosane Piccoli,Amanda Kirchner Schneider,Laiana Silla,Lúcia Mariano Bó,Suzane Dal Xavier,Ricardo Machado |
author2_role |
author author author author author author author |
dc.contributor.author.fl_str_mv |
Alegretti,Ana Paula Bittar,Christina Matzenbacher Bittencourt,Rosane Piccoli,Amanda Kirchner Schneider,Laiana Silla,Lúcia Mariano Bó,Suzane Dal Xavier,Ricardo Machado |
dc.subject.por.fl_str_mv |
Antigens, CD56 Leukemia, Myeloid Prognosis |
topic |
Antigens, CD56 Leukemia, Myeloid Prognosis |
description |
BACKGROUND: The expression of CD56 is considered a bad prognostic factor for overall survival, lower rates or short complete remission and extramedullary invasion but the results are controversial. The importance of validating new prognostic parameters in acute leukemias was the reason to investigate the CD56 expression in blast cells of patients with acute myeloid leukemia. METHODS: A cohort of 48 patients treated at Hospital de Clinicas de Porto Alegre and diagnosed with acute myeloid leukemia as classified by the French-American-British group (FAB) criteria using cell morphology, cytochemistry and flow cytometry were evaluated. RESULTS: Eight cases (16.7%) were CD56 positive without correlation to age or gender. The highest incidence of CD56 positivity was in FAB subtypes M4 and M5. The death rate during induction was not significantly different between patients with and without CD56 expression (62.5% vs. 27.5%; p-value = 0.097). However, patients that expressed CD56 had significantly lower overall survival than those who did not (mean 4.0 months vs. 14.5 months; p-value = 0.03). CONCLUSIONS: The data suggest that expression of CD56 in acute myeloid leukemia may be indicative of poor prognosis because it is associated with a shorter overall survival. The death rate during induction was not significantly different despite an apparent difference in proportions between groups. |
publishDate |
2011 |
dc.date.none.fl_str_mv |
2011-06-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842011000300012 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842011000300012 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.5581/1516-8484.20110054 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular |
publisher.none.fl_str_mv |
Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular |
dc.source.none.fl_str_mv |
Revista Brasileira de Hematologia e Hemoterapia v.33 n.3 2011 reponame:Revista brasileira de hematologia e hemoterapia (Online) instname:Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC) instacron:ABHHTC |
instname_str |
Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC) |
instacron_str |
ABHHTC |
institution |
ABHHTC |
reponame_str |
Revista brasileira de hematologia e hemoterapia (Online) |
collection |
Revista brasileira de hematologia e hemoterapia (Online) |
repository.name.fl_str_mv |
Revista brasileira de hematologia e hemoterapia (Online) - Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC) |
repository.mail.fl_str_mv |
sbhh@terra.com.br||secretaria@rbhh.org |
_version_ |
1754213111207821312 |